TY - JOUR
T1 - Technetium-99m hexakis 2-methoxyisobutyl isonitrile
T2 - Human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging
AU - Wackers, F. J.T.
AU - Berman, D. S.
AU - Maddahi, J.
AU - Watson, D. D.
AU - Beller, G. A.
AU - Strauss, H. W.
AU - Boucher, C. A.
AU - Picard, M.
AU - Holman, B. L.
AU - Fridrich, R.
AU - Inglese, E.
AU - Delaloye, B.
AU - Bischof-Delaloye, A.
AU - Camin, L.
AU - McKusick, K.
PY - 1989
Y1 - 1989
N2 - The biodistribution, dosimetry, and safety of a new myocardial imaging agent, 99m-Tc-hexakis-2-methoxyisobutyl isonitrile (HEXAMIBI), was evaluated in 17 normal volunteers at rest and exercise (Phase I studies). Technetium-99m HEXAMIBI clears rapidly from the blood with good myocardial uptake and favorable myocardial-to-background ratios for myocardial imaging. Dosimetry allows for administration of up to 30 mCi (1,110 Bq) of [99mTc]HEXAMIBI. The myocardial images were of good quality and appeared less granular with sharper myocardial walls compared to 201T1 images. The clinical efficacy of [99mTc]HEXAMIBI planar stress and rest imaging was evaluated in a multicenter Phase II clinical trial involving 38 patients. Of 36 patients with significant coronary artery disease, 35 patients (97%) had abnormal 201T1 stress images, and 32 (89%) had abnormal [99mTc]HEXAMIBI stress images (P = N.S.). Technetium-99m HEXAMIBI images correlated in 31/35 patients (86%) who had either scar or ischemia on 201T1 images. By segmental myocardial analysis, exact concordance was obtained in 463/570 myocardial segments (81%). This multicenter Phase I and II study indicates that planar [99mTc]HEXAMIBI stress imaging is safe and compares well with 201T1 stress imaging for detection of coronary artery disease.
AB - The biodistribution, dosimetry, and safety of a new myocardial imaging agent, 99m-Tc-hexakis-2-methoxyisobutyl isonitrile (HEXAMIBI), was evaluated in 17 normal volunteers at rest and exercise (Phase I studies). Technetium-99m HEXAMIBI clears rapidly from the blood with good myocardial uptake and favorable myocardial-to-background ratios for myocardial imaging. Dosimetry allows for administration of up to 30 mCi (1,110 Bq) of [99mTc]HEXAMIBI. The myocardial images were of good quality and appeared less granular with sharper myocardial walls compared to 201T1 images. The clinical efficacy of [99mTc]HEXAMIBI planar stress and rest imaging was evaluated in a multicenter Phase II clinical trial involving 38 patients. Of 36 patients with significant coronary artery disease, 35 patients (97%) had abnormal 201T1 stress images, and 32 (89%) had abnormal [99mTc]HEXAMIBI stress images (P = N.S.). Technetium-99m HEXAMIBI images correlated in 31/35 patients (86%) who had either scar or ischemia on 201T1 images. By segmental myocardial analysis, exact concordance was obtained in 463/570 myocardial segments (81%). This multicenter Phase I and II study indicates that planar [99mTc]HEXAMIBI stress imaging is safe and compares well with 201T1 stress imaging for detection of coronary artery disease.
UR - http://www.scopus.com/inward/record.url?scp=0024582126&partnerID=8YFLogxK
M3 - Article
SN - 0161-5505
VL - 30
SP - 301
EP - 311
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 3
ER -